-
公开(公告)号：US20230390304A1
公开(公告)日：2023-12-07
申请号：US18328388
申请日：2023-06-02
申请人： Lipocine Inc.
发明人： Benjamin J. Bruno , Nachiappan Chidambaram , Jonathan Ogle , Kongnara Papangkorn , Mahesh V. Patel
CPC分类号： A61K31/57 , A61K9/0053
摘要： Disclosed is a method and composition for treating CNS disorders in a subject. In an embodiment, the method preferably comprises the ordered steps of identifying a subject having or being predisposed to epilepsy, and orally administering to the subject an AED. The administration preferably comprises an administration regimen of a predetermined quantity of the AED, at a predetermined frequency, and for a predetermined duration. The subject preferably comprises a subject experiencing seizure clusters, WWE, and more especially a WWE of childbearing age. The composition preferably comprises a NAS, and more especially an ENAS. The method preferably results in the prevention, or reduced frequency or magnitude of epileptic seizures.
-
公开(公告)号：US11478485B1
公开(公告)日：2022-10-25
申请号：US17740673
申请日：2022-05-10
申请人： Lipocine Inc.
发明人： Mahesh V. Patel , Nachiappan Chidambaram , Kilyoung Kim , Kongnara Papangkorn , Benjamin J. Bruno , Kiran Kumar Vangara
摘要： The present disclosure is drawn to compositions and methods for treating CNS disorders. In one embodiment, an oral pharmaceutical composition can comprise a therapeutically effective amount of pregn-4-ene-3,20-dione; and a pharmaceutically acceptable carrier that provides formation of either 3α-OH-5α-pregnan-20-one, or 3α-OH-5β-pregnan-20-one, or both in an amount sufficient to treat a CNS disorder when orally administered to a subject. In another embodiment, a method of treating a CNS disorder can comprise orally administering to a subject, a therapeutically effective amount of pregn-4-ene-3,20-dione that provides an amount of GABA receptor binding pregn-4-ene-3,20-dione metabolites that is sufficient to treat the CNS disorder. In another embodiment, a method of treating a CNS disorder can comprise orally administering to the subject, a therapeutically effective amount of pregn-4-ene-3,20-dione that provides an amount of 3α-OH-5α-pregnan-20-one, or 3α-OH-5β-pregnan-20-one, or both that is sufficient to treat the CNS disorder.
-
公开(公告)号：US20240252513A1
公开(公告)日：2024-08-01
申请号：US18619033
申请日：2024-03-27
申请人： Lipocine Inc.
发明人： Jonathan Ogle , Benjamin J. Bruno , Kongnara Papangkorn , Samuel Akapo , Joel Frank , Nachiappan Chidambaram , Mahesh V. Patel
CPC分类号： A61K31/57 , A61K9/0053 , A61K9/14 , A61K31/557 , A61P15/06 , A61P21/00
摘要： Disclosed is a method and an oral composition for treating CNS disorders. An embodiment of the invention comprises orally administering an allopregnanolone containing composition to a subject having a CNS disorder. Exemplary CNS disorders include sleep disorders, mood disorders, dysthymic disorders, bipolar disorders, anxiety disorders, stress disorders, compulsive disorders, schizophrenia spectrum disorders, convulsive disorders, memory disorders, cognition disorders, movement disorders, personality disorders, autism spectrum disorders, substance abuse disorders, dementia, pain, traumatic brain injury (TBI), vascular disease, withdrawal syndrome, and tinnitus. The composition and methods disclosed herein exhibit effective oral absorption/bioavailability.
-
公开(公告)号：US11337987B1
公开(公告)日：2022-05-24
申请号：US17314883
申请日：2021-05-07
申请人： Lipocine Inc.
发明人： Mahesh V. Patel , Nachiappan Chidambaram , Kilyoung Kim , Kongnara Papangkorn , Benjamin J. Bruno , Kiran Kumar Vangara
摘要： The present disclosure is drawn to compositions and methods for treating CNS disorders. In one embodiment, an oral pharmaceutical composition can comprise a therapeutically effective amount of pregn-4-ene-3,20-dione; and a pharmaceutically acceptable carrier that provides formation of either 3α-OH-5α-pregnan-20-one, or 3α-OH-5β-pregnan-20-one, or both in an amount sufficient to treat a CNS disorder when orally administered to a subject. In another embodiment, a method of treating a CNS disorder can comprise orally administering to a subject, a therapeutically effective amount of pregn-4-ene-3,20-dione that provides an amount of GABA receptor binding pregn-4-ene-3,20-dione metabolites that is sufficient to treat the CNS disorder. In another embodiment, a method of treating a CNS disorder can comprise orally administering to the subject, a therapeutically effective amount of pregn-4-ene-3,20-dione that provides an amount of 3α-OH-5α-pregnan-20-one, or 3α-OH-5β-pregnan-20-one, or both that is sufficient to treat the CNS disorder.
-
公开(公告)号：US11969434B1
公开(公告)日：2024-04-30
申请号：US17823080
申请日：2022-08-29
申请人： Lipocine Inc.
发明人： Jonathan Ogle , Benjamin J. Bruno , Kongnara Papangkorn , Samuel Akapo , Joel Frank , Nachiappan Chidambaram , Mahesh V. Patel
CPC分类号： A61K31/57 , A61K9/0053 , A61K9/14 , A61K31/557 , A61P15/06 , A61P21/00
摘要： Disclosed is a method and an oral composition for treating CNS disorders. An embodiment of the invention comprises orally administering an allopregnanolone containing composition to a subject having a CNS disorder. Exemplary CNS disorders include sleep disorders, mood disorders, dysthymic disorders, bipolar disorders, anxiety disorders, stress disorders, compulsive disorders, schizophrenia spectrum disorders, convulsive disorders, memory disorders, cognition disorders, movement disorders, personality disorders, autism spectrum disorders, substance abuse disorders, dementia, pain, traumatic brain injury (TBI), vascular disease, withdrawal syndrome, and tinnitus. The composition and methods disclosed herein exhibit effective oral absorption/bioavailability.
-
公开(公告)号：US20230101470A1
公开(公告)日：2023-03-30
申请号：US17512365
申请日：2021-10-27
申请人： Lipocine Inc.
IPC分类号： A61K31/573 , A61K9/00 , A61P15/06
摘要： An HPC composition and method of treatment for the prevention of PTB and improved neonatal outcomes. The invention provides for a dosing regimen beginning as early as 14 weeks of fetal gestation and dosing regimens of a duration of as much as 25 weeks. The invention provides a high level of exogeneous progestin to endogenous progesterone when it is most needed. The instant invention consistently achieves active levels of HPC which achieve effectiveness. Exemplary dosing regimens comprise an oral administration of HPC in the range of 1,200 mg to 1600 mg, wherein the HPC is administered via a once a day, twice a day, or three times a day administration.
-
公开(公告)号：US20240173335A1
公开(公告)日：2024-05-30
申请号：US17937934
申请日：2022-10-04
申请人： Lipocine Inc.
发明人： Jonathan Ogle , Benjamin J. Bruno , Kongnara Papangkorn , Samuel Akapo , Joel Frank , Nachiappan Chidambaram , Mahesh V. Patel
CPC分类号： A61K31/57 , A61K9/0053 , A61K9/20 , A61K9/48 , A61P25/24
摘要： Disclosed is a method and an oral composition for treating CNS disorders. An embodiment of the invention comprises orally administering an allopregnanolone containing composition to a subject having a CNS disorder. Exemplary CNS disorders include sleep disorders, mood disorders, dysthymic disorders, bipolar disorders, anxiety disorders, stress disorders, compulsive disorders, schizophrenia spectrum disorders, convulsive disorders, memory disorders, cognition disorders, movement disorders, personality disorders, autism spectrum disorders, substance abuse disorders, dementia, pain, traumatic brain injury (TBI), vascular disease, withdrawal syndrome, and tinnitus. The composition and methods disclosed herein exhibit effective oral absorption/bioavailability.
-
公开(公告)号：US20240156837A1
公开(公告)日：2024-05-16
申请号：US17929895
申请日：2022-09-06
申请人： Lipocine Inc.
发明人： Mahesh V. Patel , Nachiappan Chidambaram , Kilyoung Kim , Kongnara Papangkorn , Benjamin J. Bruno , Kiran Kumar Vangara
CPC分类号： A61K31/57 , A61K9/0053 , A61P25/24 , A61K9/4825
摘要： The present disclosure is drawn to compositions and methods for treating CNS disorders. In one embodiment, an oral pharmaceutical composition can comprise a therapeutically effective amount of pregn-4-ene-3,20-dione; and a pharmaceutically acceptable carrier that provides formation of either 3α-OH-5α-pregnan-20-one, or 3α-OH-5β-pregnan-20-one, or both in an amount sufficient to treat a CNS disorder when orally administered to a subject. In another embodiment, a method of treating a CNS disorder can comprise orally administering to a subject, a therapeutically effective amount of pregn-4-ene-3,20-dione that provides an amount of GABA receptor binding pregn-4-ene-3,20-dione metabolites that is sufficient to treat the CNS disorder. In another embodiment, a method of treating a CNS disorder can comprise orally administering to the subject, a therapeutically effective amount of pregn-4-ene-3,20-dione that provides an amount of 3α-OH-5α-pregnan-20-one, or 3α-OH-5β-pregnan-20-one, or both that is sufficient to treat the CNS disorder.
-
公开(公告)号：US20220354867A1
公开(公告)日：2022-11-10
申请号：US17740673
申请日：2022-05-10
申请人： Lipocine Inc.
发明人： Mahesh V. Patel , Nachiappan Chidambaram , Kilyoung Kim , Kongnara Papangkorn , Benjamin J. Bruno , Kiran Kumar Vangara
摘要： The present disclosure is drawn to compositions and methods for treating CNS disorders. In one embodiment, an oral pharmaceutical composition can comprise a therapeutically effective amount of pregn-4-ene-3,20-dione; and a pharmaceutically acceptable carrier that provides formation of either 3α-OH-5α-pregnan-20-one, or 3α-OH-5β-pregnan-20-one, or both in an amount sufficient to treat a CNS disorder when orally administered to a subject. In another embodiment, a method of treating a CNS disorder can comprise orally administering to a subject, a therapeutically effective amount of pregn-4-ene-3,20-dione that provides an amount of GABA receptor binding pregn-4-ene-3,20-dione metabolites that is sufficient to treat the CNS disorder. In another embodiment, a method of treating a CNS disorder can comprise orally administering to the subject, a therapeutically effective amount of pregn-4-ene-3,20-dione that provides an amount of 3α-OH-5α-pregnan-20-one, or 3α-OH-5β-pregnan-20-one, or both that is sufficient to treat the CNS disorder.
-
-
-
-
-
-
-
-
搜索结果
9 条记录 (耗时 0.014 秒)
